As the U.S. continues to prioritize onshoring of R&D and manufacturing, life science companies are investing heavily to expand their operations. Industry leaders like Roche, Novartis, Abbott, and Eli Lilly are committing $30–$50 billion in real estate investment over the next decade, driven by federal incentives, tariff changes, and a growing pipeline of approved therapies. 

But with high land and labor costs, increasingly stringent building codes and sustainability demands, and 70% of construction projects still running over budget and behind schedule, the pressure is on to rethink how facilities are delivered across all major hubs - from San Francisco to San Diego, Los Angeles, Orange County, and Seattle. 

That’s why Advancing Life Science Construction West 2025 is coming to San Diego this December – to support the life science construction community across western states to tackle regional challenges head-on and connect with peers who understand the landscape. 

Whether you're building a new R&D campus or upgrading existing mixed-use facilities, this event provides the tools, insights, and connections to uncover the future pipeline, and deliver higher-quality, compliant, and sustainable projects, on time and on budget.